#GUCancer hashtag - Bluesky

3 weeks ago

Things are in full swing at the 19th Annual NY GU Cancers Congress! Check back at onclive.com for all of our coverage of the meeting #oncology #medtwitter #kcsm #GUcancer

0 0 0 0

1 month ago

🎥 This year at @ascocancer.bsky.social #GU26, we asked our interviewees which abstracts they were most looking forward to seeing at the meeting and their must-have food or drink for a conference!
#oncology #RCC #kcsm #GUcancer #ASCOGU2026
Hear what they had to say below:

0 0 0 0

1 month ago

The presentations are in full swing at our National Fellows Forum ahead of #ASCOGU2026. Stay tuned to onclive.com for all of our coverage! #oncology #GUcancer

0 0 0 0

DISCUS: comparing 3 vs 6 chemotherapy cycles before avelumab in aUC - VJOncology Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the Phase II DISCUS trial (NCT06892860), which evaluated whether...

1 month ago

Ahead of #ASCOGU2026 we are live in San Francisco for our National Fellows Forum: Genitourinary Cancer! Stay tuned to onclive.com for our coverage of exciting research by fellows from across the country. #oncology #GUcancer

0 0 0 0

VJOncology

@vjoncology.bsky.social

5 months ago

At #ESMO25, Enrique Grande, MD, presents results from the Phase II DISCUS trial in aUC.

💊 3 vs 6 chemo cycles before avelumab maintenance
📈 Similar OS & PFS
💪 Better QoL & fewer toxicities with 3 cycles

🎥 buff.ly/UjqkfNT

@myesmo.bsky.social #BladderCancer #ImmunoOnc #GUcancer #Oncology

0 0 0 0

5 months ago

Some patients with PTEN-deficient mHSPC may progress before PSA rises, says Elena Castro Marcos. We need smarter monitoring and better biomarkers to guide treatment decisions, and spare patients from unnecessary toxicity

#ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #GUCancer

1 1 0 0

5 months ago

Karim Fizazi: “PTEN loss drives aggressive prostate cancer. Targeting this biology can make a real difference.”

📉 Significant delay in progression
📊 Benefit increases with extent of PTEN loss
⚠️ Safety profile consistent with known effects

#ESMO25 #OncSky #MedEd #MedSky #ProstateCancer #GUCancer

1 1 1 0

5 months ago

Treatment intensification earlier in high-risk biochemical recurrence may prolong survival, says Derya Tilki. Smarter use of imaging and timing, plus targeted approaches, could help patients live longer with fewer interventions

#ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #GUCancer

1 1 1 0

5 months ago

@sfreedlandmd.bsky.social: “It’s a great day for our patients.”

8-year survival in high-risk BRPC reached nearly 80%. The takeaway? Earlier intensification reduced death risk by >40%, with no new safety concerns

#ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #GUCancer

1 1 1 0

5 months ago

Rahul Aggarwal shares final results in high-risk BRPC:

📊 PSA-PFS improved
⏳ Time to castration resistance prolonged
🧬 Benefit seen even after testosterone recovery
⚠️ Toxicity manageable

#ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #GUCancer

1 1 1 0

5 months ago

“Behind every rare cancer trial is immense effort, and a patient waiting for better options.” - Gunhild von Amsberg at #ESMO25

In penile cancer & seminoma, we must balance efficacy with long-term toxicity and push for smarter, biomarker-driven care

#OncSky #MedSky #Oncology #GUCancer

0 0 0 0

5 months ago

💭“We need biomarkers to better identify who benefits,” says Srikala Sridhar at #ESMO25

In a rare and aggressive cancer with limited options, a new immunotherapy approach is showing durable responses for some patients with advanced penile cancer

#MedSky #OncSky #Oncology #GUCancer

0 0 0 0

5 months ago

“Early results are encouraging, but we must stay grounded, patients need treatments that are not just effective, but tolerable and tailored.” - Pasquale Rescigno at #ESMO25.

Immune context, dosing, and patient experience all matter!

#ProstateCancer #GUCancer #OncSky #MedSky

0 0 0 0

5 months ago

💭Time to hear from one of our chairs @yukselurun.bsky.social!

“Not all patients need intensified treatment, new trials highlight the need for tailored, tolerable, quality of life-conscious care.”

#ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #GUCancer

2 1 0 0

5 months ago

Patients maintained baseline QoL after an initial, manageable dip—likely linked to early side effects, says Dana Rathkopf on new trial data in HRR-mutated mHSPC. The takeaway? Promising clinical benefit without long-term QoL compromise

#ESMO25 #ProstateCancer #GUCancer #OncSky #MedSky

1 1 0 0

5 months ago

What’s new in genitourinary oncology at #ESMO25?

From mHSPC treatment updates to novel agents in mCRPC, penile, and testicular cancer, follow along for live updates and key takeaways in advancing #oncology care

#OncSky #MedEd #MedSky #ProstateCancer #GUCancer

1 1 0 0